This trial is evaluating whether Continuous glucose monitor will improve 2 primary outcomes in patients with Diabetes, Gestational. Measurement will happen over the course of 4 years.
This trial requires 100 total participants across 2 different treatment groups
This trial involves 2 different treatments. Continuous Glucose Monitor is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Diabetes affected 8.3% of US women in 2006 and 5% in 2008/2009. Of women presenting for care, diabetes prevalence varied substantially by region, ethnicity, age and obesity. Diabetes prevalence in US births was 7.7% in 2006/2007. In the absence of a national diabetes surveillance program and reporting requirements, current estimates of diabetes prevalence in US women of childbearing age and US pregnant women are not reliable to understand the prevalence of diabetes and its complications in the US population.
Diabetes during pregnancy increases the risk of most of the serious adverse outcomes of pregnancy. Gestational diabetes is characterized by insulin imbalance, gestational hypertension, and fetal macrosomia/microsomia (fetal growth patterns).\n
With proper management, gestational diabetes can be cured. However, it should be recognized that pregnancy can be a stressful experience for both women and their unborn babies. With appropriate advice and supportive care, gestational diabetes and pregnancy can lead to successful pregnancies with healthy babies.
The pathogenesis of diabetes, gestational is multifactorial, and the major pathophysiological mechanisms are insulin resistance and impaired insulin secretion. The key to the genesis of gestational diabetes is an increased secretion of proinflammatory cytokines, and a decreased insulin secretion.
Diabetes in pregnancy is characterized by nausea and vomiting, thirst and frequent urination. Other signs of diabetes include an elevated blood glucose level and gestational diabetes. Pregnancy can occur in women with diabetes and without a history of the illness.
There is increased knowledge, and a tendency to focus on prevention and treatments of diabetes. As knowledge and understanding of diabetes evolves, there is a need to provide information and support for people with diabetes and their families. It is important that healthcare providers have information and support for people with diabetes and their families.
We suggest the use of CGM in patients not only using multiple treatments but also in those with a long duration of diabetes (e.g. more than 5 years). In the patients who have been treated with insulin for more than 5 years, the effects of long-term use of insulin on blood glucose and insulin sensitivity may be a contraindication for CGM use. However, the potential benefits of CGM should be weighed against the risks of using it.
On the basis of the present data, it would appear that CGMS has proven to minimize glucose variability, with less hypoglycemic events in comparison to control group. Therefore, this promising device seems to be potentially useful in type 2 diabetes management, especially with regard to the patients not achieving glycemic control through conventional pharmacological therapies.
Diabetes, gestational diabetes, and gestational hypertension have low absolute and relative contribution to clinical trials but should all be screened. The majority of women consider clinical trials for gestational diabetes.
CGMs resulted in meaningful reductions in glycemia in all respondents, despite a few shortcomings. There was minimal impact on the overall QOL or bother, except for those who reported a sense of well-being.
In a recent study, findings of this study suggest that women with diabetes or gestational diabetes have increased insulin resistance when compared to women without diabetes. Although secondary insulin resistance did not increase significantly from baseline to 24-28 weeks gestation, it increased significantly from 28 to 32 weeks and was significantly higher than baseline at 36 weeks gestation when compared to women with gestational diabetes with secondary insulin resistance. We speculate that the cause of this increased secondary insulin resistance may be related to the pregnancy process.